Amneal Makes Second US Biosimilar Launch With Filgrastim
Releuko Version Of Neupogen Follows Alymsys Bevacizumab Rival To Avastin
Following Amneal’s first biosimilar launch last month, the company has made it two with the introduction of its Releuko version of filgrastim in the US. It plans to complete the trinity with its Fylnetra pegfilgrastim biosimilar early next year.
